Advertisement
LIPO 外匯新聞
Lipella Pharma Soars 48% After FDA Oks IND For LP-310 For Oral Lichen Planus
Biotechnology company Lipella Pharmaceuticals Inc. (LIPO) announced Friday that the U.S. Food and Drug Administration (FDA) has approved an Investigational New Drug (IND) application for a multi-center, phase-2a, dose-escalation clinical trial.
RTTNews
|
555天前
Lipella Pharma Announces Top Line Results In Phase 2A Trial Of LP-10 For Hemorrhagic Cystitis
Biotechnology company Lipella Pharmaceuticals Inc. (LIPO) announced top line results for its recently completed Phase 2a clinical trial evaluating the safety and efficacy of its drug candidate LP-10 for Hemorrhagic Cystitis, a rare but highly morbid disease for which there are currently no FDA approved treatments.
RTTNews
|
837天前
